ClinicalTrials.gg
CompletedNCT05150340Updated Nov 25, 2024Results posted

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

A Phase 3 interventional study of TAK-771 in Primary Immunodeficiency Diseases (PID), sponsored by Takeda. Completed at 12 sites in Japan. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.

Enrollment
14th of 18
16 · median 47
Started
2022
with 1 other
Phase 3
9 of 23
none open now
Registered
16th of 23
by date

Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 14th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 16th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Primary Immunodeficiency Diseases by Takeda, or all of them as a file.
02

Study summary

The main aim of the study is to check how much TAK-771 stays in their blood over time, side effect from the study treatment or TAK-771, how much TAK-771 participants can receive without getting side effects from it, and if TAK-771 improves symptoms of primary immunodeficiency diseases (PID). This will help the study sponsor (Takeda) to work out the best dose to give people in the future.

The participants will be treated with TAK-771 for totally 27 or 30 weeks. Treatment period is consist of two periods called Epoch 1 and Epoch 2. In Epoch 1, different groups of participants will receive lower to higher doses of TAK-771 for 3 to 6 weeks. The study doctors will check for side effects from each dose of TAK-771. In Epoch 2, participants will receive TAK-771 once a 3 or 4 weeks until the end of 24 weeks.

There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 3, or 4 weeks).

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be a Japanese person.
  2. Participant must have a documented diagnosis of a form of primary humoral immunodeficiency involving antibody formation and requiring gammaglobulin replacement, as defined according to the International Union of Immunological Societies(IUIS) Committee 2017. The diagnosis must be confirmed by the Medical Director prior to TAK-771 treatment.
  3. Participant has been receiving a stable clinical dose of intravenous immunoglobulin (IVIG) or conventional subcutaneous immunoglobulin (cSCIG), which is equivalent to approximately 200 to 600 mg/kg body weight per 3 to 4 week period for IVIG and approximately 50 to 200 mg/kg body weight per week for cSCIG based on the description in the package insert, consistently over a period of at least 3 months prior to screening, or Participant has been receiving of TAK-664 with fixed dose and dosing frequency at least 3 months prior to enrollment. That is, participant is about to complete Study TAK-664-3001 or participating in Study TAK-664-3002.
  4. Participant who has been receiving IVIG or cSCIG had all serum trough levels of total immunoglobulin G (IgG) >=5 g/L within 1 month prior to the screening/enrollment.
  5. Serum trough levels at screening/enrollment meet one of the following:

    1. IVIG-treated or cSCIG-treated participants Participant who had serum trough levels of IgG >=5 g/L at the last 2 points in screening procedure before the first administration of TAK-771.
    2. TAK-664-treated participants Participant who had serum trough levels of IgG >=5 g/L at the last 2 points in TAK-664 studies before the first administration of TAK-771.
  6. Participant is willing and able to comply with use of digital tools and applications.

Exclusion criteria

Exclusion Criteria

  1. Participant has a known history of or is positive at screening/enrollment for one or more of the following: surface antigen (HBsAg), polymerase chain reaction (PCR) for virus (HCV), PCR for (HIV) Type 1/2 For participants who are switching from TAK-664 studies, the eligibility will be reconfirmed after result of the specialty test conducted at Week 1 become available.
  2. Abnormal laboratory values at screening/enrollment meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):

    • Persistent (ALT) and aspartate aminotransferase (AST) >2.5 times the (ULN) for the testing laboratory
    • Persistent severe neutropenia (defined as an [ANC] =\<500/mm\^3)
  3. Participant has presence of renal function impairment defined by \<60 mL/min/1.73m\^2.
  4. Participant has been diagnosed with, or had a (other than adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the disease-free period prior to screening exceeds 5 years.
  5. Participant is receiving anti-coagulation therapy or has a history of thrombotic episodes (including deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism) within 12 months prior to screening/enrollment or a history of thrombophilia.
  6. Participant has abnormal protein loss (protein losing enteropathy, nephrotic syndrome)
  7. Participant has anemia that would preclude phlebotomy for laboratory studies according to standard practice at the site.
  8. Participant has an ongoing history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IVIG, subcutaneous immunoglobulin (SCIG), and/or Immune Serum Globulin infusions
  9. Participant has immunoglobulin A (IgA) deficiency (serum IgA less than 0.07g/L) and history of hypersensitivity, or history of confirmed anti-IgA antibodies, or both.
  10. Participant is on preventative (prophylactic) systemic antibacterial antibiotics at doses sufficient to treat or prevent bacterial infections, and cannot stop these antibiotics at the time of screening/enrollment.
  11. Participant has active infection and is receiving antibiotic therapy for the treatment of infection at the time of screening/enrollment or had a serious bacterial infection within the 3 months prior to screening/enrollment
  12. Participant has a bleeding disorder, or a count less than 20,000/microL, or in the opinion of the investigator, would be at significant risk of increased bleeding or bruising as a result of subcutaneous (SC) therapy.
  13. Participant has total protein >9 g/dL or myeloma, or macroglobulinemia (IgM) or paraproteinemia.
  14. Participant has a known allergy to hyaluronidase
  15. Participant has severe dermatitis that would preclude adequate sites for safe product administration.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Epoch 1: TAK-771 Ramp up Period

    TAK-771 included IGI 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants received subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution. The dose of 10% IGI was increased from 1/3 of full dose to full dose in 3 weeks for participants who received TAK-771 once every 3 weeks, or from 1/4 of full dose to full dose in 6 weeks for participants who received TAK-771 once every 4 weeks.

    Drug: TAK-771

  • Experimental
    Epoch 2: TAK-771 Full Dose Treatment Period

    TAK-771 included Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants received subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 3, or 4 weeks for up to Week 27 for participants with 4-Week dosing interval or Week 25 for participants with 3-Week dosing interval.

    Drug: TAK-771

Interventions

  • Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)

    Also known as: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

06

What researchers measure

Primary outcomes

  1. Epoch 2: Serum Trough Levels of Total IgG Antibodies After Administration of TAK-771

    The data was reported at Week 7, 11, 15, 19, 23, 27, and 31 for 4-Week interval and at Week 4, 7, 10, 13, 16, 19, 22, 25 and 28 for 3-Week interval.

    Time frame: Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval

Secondary outcomes

  1. Epoch 2: Maximum Concentration (Cmax) of Total Serum Levels of IgG and IgG Subclasses

    Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.

  2. Epoch 2: Time to Maximum Concentration (Tmax) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)

    Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.

  3. Epoch 2: Area Under the Curve (AUC) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)

    AUC is expressed as grams\*day per liter/grams per kilograms \[(g\*day/L)/(g/kg)\].

    Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.

  4. Epoch 2: Half-life of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)

    Time frame: At multiple time points post-infusion from Week 7 for participants with 4-Week or Week 4 with 3-Week dosing interval up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval

  5. Epoch 2: Apparent Total Clearance (CL/F) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)

    Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.

  6. Epoch 2: Apparent Volume of Distribution (Vz/F) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)

    Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.

  7. Epoch 2: Minimum Concentration (Cmin) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)

    Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.

  8. Epoch 2: Serum Trough Levels of IgG Subclasses (IgG1, IgG2, IgG3, and IgG4) After Administration of TAK-771

    Time frame: 4-Week dosing interval (Week 7, Week 11, Week 15, Week 19, Week 23, Week 27, and Week 31); 3-Week dosing interval (Week 4, week 7, Week 10, Week 16, Week 19, Week 22, Week 25, and Week 28)

  9. Epoch 1 and 2: Trough Levels of Anti-Clostridium Tetani Toxoid Antibody After Administration of TAK-771

    Time frame: From Week 1, up to end of trial (EOS: Week 31 for participants with 4-Week dosing interval or Week 28 for participants with 3-Week dosing interval)

  10. Epoch 1 and 2: Trough Levels of Anti-HBV Antibody After Administration of TAK-771

    Time frame: From Week 1, up to end of trial (EOS: Week 31 for participants with 4-Week dosing interval or Week 28 for participants with 3-Week dosing interval)

  11. Epoch 1 and 2: Trough Levels of Anti-HIB Antibody After Administration of TAK-771

    Time frame: From Week 1, up to end of trial (EOS: Week 31 for participants with 4-Week dosing interval or Week 28 for participants with 3-Week dosing interval).

  12. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    TEAEs are defined as Adverse events (AEs) with onset after date-time of first dose of Investigational product (IP), or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP.

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  13. Percentage of Participants With TAK-771-Related and TAK-771-Non-Related TEAEs

    TEAEs are defined as AEs with onset after date-time of first dose of IP, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP.

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  14. Percentage of Participants With Serious and Non-serious TEAEs

    TEAEs are defined as AEs with onset after date-time of first dose of IP, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Serious TEAE=any untoward clinical manifestation of signs, symptoms, outcomes (related to IP or not) at any dose: results in death, was life-threatening, requires inpatient/prolongation of hospitalization, resulted in persistent/significant disability/incapacity, congenital abnormality/birth defect, important medical event. AESI=investigator-reported hypersensitivity reactions, events of disordered coagulation as bleeding/hypercoagulable AESI.

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  15. Percentage of Participants With Severe TEAEs

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  16. Percentage of Participants With Local and Systemic TEAEs

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  17. Percentage of Participants With TEAEs Leading to Premature Discontinuation From Study

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  18. Percentage of Participants With Infusion-associated TEAEs

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  19. Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Parameters Recorded as TEAEs

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  20. Percentage of Participants With Clinically Significant Changes in Vital Signs and Body Weight Recorded as TEAEs

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  21. Epoch 2: Percentage of Participants Who Develop Anti-rHuPH20 Binding Antibody Titers of Greater Than or Equal to 1:160

    Time frame: 4-Week Dosing Interval (Week 7, Week 19, and Week 31); 3-Week Dosing Interval (Week 4, Week 16, and Week 28)

  22. Epoch 2: Percentage of Participants Who Develop Neutralizing Antibodies to rHuPH20

    Time frame: 4-Week Dosing Interval (Week 7, Week 19, and Week 31); 3-Week Dosing Interval (Week 4, Week 16, and Week 28)

  23. Percentage of Participants Who Experienced Tolerability Events Related to the Infusion of TAK-771

    Tolerability events is defined as a case that the infusion rate is reduced, or that the infusion is interrupted or stopped, due to a TEAE related to TAK-771 infusion.

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  24. Epoch 1: Number of Weeks to Reach Final Dose Interval (3 Weeks or 4 Weeks)

    The number of weeks to reach final dose interval is defined as treatment duration of Epoch 1.

    Time frame: Up to Week 4 for Participants with 4-Week Dosing Interval or Up to Week 3 for Participants with 3-Week Dosing Interval

  25. Epoch 2: Percentage of Participants Who Achieve a Treatment Interval of 3 or 4 Weeks

    Time frame: Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval

  26. Epoch 2: Percentage of Participants Who Maintain a Treatment Interval of 3 or 4 Weeks

    Time frame: Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval

  27. Annual Rate of Validated Acute Serious Bacterial Infections (ASBIs) Per Participant Per Year

    The annual rate of validated ASBIs is calculated as the mean number of ASBIs per participant per year.

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  28. Annual Rate of All Infections Per Participant Per Year

    The annual rate of all infections is calculated as the mean number of infections per participant per year.

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  29. Healthcare Resource Utilization: Days Not Able To Attend School/Work or To Perform Normal Daily Activities Due to Illness/Infection

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  30. Healthcare Resource Utilization: Days on Antibiotics

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  31. Healthcare Resource Utilization: Number of Hospitalizations Due to Illness/Infection Per Year

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  32. Healthcare Resource Utilization: Length of Stay in Days of Hospitalizations Due to Illness/Infection Per Participant Per Year

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  33. Healthcare Resource Utilization: Number of Acute (Urgent or Unscheduled) Physician Visits Due to Illness/Infection

    Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval

  34. Infusion Parameters in Epoch 2: Number of Infusion Sites Per Infusion

    Total number of infusion sites injected in Epoch 2 / Total number of infusions administered in Epoch 2.

    Time frame: From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval

  35. Infusion Parameters in Epoch 2: Number of Infusion Sites Per Month

    Total number of infusion sites injected in Epoch 2 / (duration of Epoch 2 / 30.4375), where duration of Epoch 2 is calculated as the end date of the Epoch 2 - the start date of the Epoch 2 + 1.

    Time frame: From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval

  36. Infusion Parameters in Epoch 2: Duration of Individual Infusions

    End date and time of infusion in Epoch 2 - Start date and time of infusion in Epoch 2, for each infusion per participant.

    Time frame: From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval

  37. Infusion Parameters in Epoch 2: Maximum Infusion Rate Per Site

    Maximum Infusion Rate results from CRF / number of infusion sites/body.

    Time frame: From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval

  38. Infusion Parameters in Epoch 2: Infusion Volume Per Site

    Infusion Volume per Site is scheduled Dose results from CRF / number of infusion sites/body.

    Time frame: From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval

  39. Quality of Life (QOL): Pediatric Quality of Life Inventory (PEDS-QL)

    The PEDS-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. In this study, 2-7 years (parent as observer), 8-13 years (participant as observer) for PEDS-QL health questionnaire will be analyzed. Higher scores indicate better quality of life (QOL) for all domains of the PEDS-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Four dimensions (physical, emotional, social, \& school functioning) are scored.

    Time frame: 4-Week Dosing Interval (Week 1 and Week 31); 3-Week Dosing Interval (Week 1 and Week 28)

  40. QOL: Short Form-36 Health Survey Version 2 (SF-36 v2)

    The SF-36 is a generic quality-of-life instrument that has been widely used to assess Health-Related Quality of Life (HR QoL) of participants. In this study, 14 years and older (participant as observer) for SF-36 health questionnaire will be analyzed. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HR QoL. Physical component summary (PCS).

    Time frame: 4-Week Dosing Interval (Week 1 and Week 31); 3-Week Dosing Interval (Week 1 and Week 28)

  41. QOL: EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Health Questionnaire Index Score

    The EQ-5D-3L is a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. Participants select answer for each of the following 3-level dimensions: 1) mobility; 2) self-care; 3) usual activities; 4) pain/discomfort; 5) anxiety/depression used to compute an index score ranging from 0 (worst imaginable health state) to 1 (best imaginable health state). An increase in the EQ-5D-3L index score indicates improvement.

    Time frame: 4-Week dosing interval (Week 1 and Week 31); 3-Week dosing interval (Week 1 and Week 28)

  42. QOL: EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Health Questionnaire Visual Analogue Scale (VAS) Score

    The EQ-5D-3L is a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. The EQ-5D-3L includes a visual analog scale (VAS), a vertical scale that allows the participants to indicate their health state that day, and ranges from 0 (worst imaginable) to 100 (best imaginable), with higher scores indicating better health state.

    Time frame: 4-Week dosing interval (Week 1 and Week 31); 3-Week dosing interval (Week 1 and Week 28)

  43. Treatment Preference

    Treatment preference questionnaire is a self-administered questionnaire developed to assess participants' preference towards the administration of new subcutaneous immunoglobulin (SCIG) therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin (IG) therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment.

    Time frame: Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval

  44. Treatment Satisfaction: Questionnaire for Medication-9 (TSQM-9)

    Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. In this study, 2-12 years (parent as observer), 13 years and older (participant as observer) for TSQM health questionnaire will be analyzed. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.

    Time frame: 4-Week dosing interval (Week 1 and Week 31); 3-Week dosing interval (Week 1 and Week 28)

07

Results

Posted Nov 25, 2024

Participant flow

Participants with a confirmed diagnosis of primary immunodeficiency diseases (PID) took part in the study at 12 investigative sites in Japan from 24 January 2022 to 28 August 2023.

Epoch 1
Participant flow — Epoch 1
MilestoneEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Started160
Pharmacokinetic analysis set 1160
Pharmacokinetic analysis set 200
Completed160
Not completed00
Epoch 2
Participant flow — Epoch 2
MilestoneEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Started016
Pharmacokinetic analysis set 1016
Pharmacokinetic analysis set 204
Completed016
Not completed00

Outcome measures

PrimaryEpoch 2: Serum Trough Levels of Total IgG Antibodies After Administration of TAK-771

The data was reported at Week 7, 11, 15, 19, 23, 27, and 31 for 4-Week interval and at Week 4, 7, 10, 13, 16, 19, 22, 25 and 28 for 3-Week interval.

Time frame:
Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Geometric mean · grams/Liter (g/L)
Epoch 2: Serum Trough Levels of Total IgG Antibodies After Administration of TAK-771
grams/Liter (g/L)Epoch 2: TAK-771 Full Dose Treatment Period
Week 7, 4-Week Interval9.372 ± 10.3
Week 11, 4-Week Interval8.741 ± 13.7
Week 15, 4-Week Interval8.929 ± 13.0
Week 19, 4-Week Interval9.150 ± 15.5
Week 23, 4-Week Interval8.944 ± 20.9
Week 27, 4-Week Interval9.006 ± 18.4
Week 31, 4-Week Interval9.159 ± 20.8
Week 4, 3-Week Interval13.51 ± 29.7
Week 7, 3-Week Interval13.15 ± 35.7
Week 10, 3-Week Interval12.54 ± 43.2
Week 16, 3-Week Interval13.50 ± 39.7
Week 19, 3-Week Interval12.76 ± 46.9
Week 22, 3-Week Interval12.79 ± 40.1
Week 25, 3-Week Interval12.95 ± 57.6
Week 28, 3-Week Interval12.70 ± 43.0
SecondaryEpoch 2: Maximum Concentration (Cmax) of Total Serum Levels of IgG and IgG Subclasses
Time frame:
Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Reported as:
Geometric mean · g/L
Epoch 2: Maximum Concentration (Cmax) of Total Serum Levels of IgG and IgG Subclasses
g/LEpoch 2: TAK-771 Full Dose Treatment Period
Total IgG12.72 ± 23.4
IgG Subclass (IgG 1)7.694 ± 16.7
IgG Subclass (IgG 2)4.140 ± 23.0
IgG Subclass (IgG 3)0.2396 ± 46.7
IgG Subclass (IgG 4)0.3200 ± 36.3
SecondaryEpoch 2: Time to Maximum Concentration (Tmax) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
Time frame:
Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Reported as:
Median · days
Epoch 2: Time to Maximum Concentration (Tmax) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
daysEpoch 2: TAK-771 Full Dose Treatment Period
Total IgG6.94 (2.94 to 8.85)
IgG Subclass (IgG 1)3.92 (2.94 to 8.83)
IgG Subclass (IgG 2)3.92 (2.94 to 8.83)
IgG Subclass (IgG 3)2.99 (2.80 to 8.83)
IgG Subclass (IgG 4)3.88 (2.80 to 5.04)
SecondaryEpoch 2: Area Under the Curve (AUC) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)

AUC is expressed as grams\*day per liter/grams per kilograms \[(g\*day/L)/(g/kg)\].

Time frame:
Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Reported as:
Geometric mean · (g*day/L)/(g/kg)
Epoch 2: Area Under the Curve (AUC) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
(g*day/L)/(g/kg)Epoch 2: TAK-771 Full Dose Treatment Period
Total IgG, AUCtau/Dose767.9 ± 40.0
Total IgG, AUClast/Dose625.6 ± 55.2
IgG Subclass (IgG 1), AUCtau/Dose432.4 ± 36.2
IgG Subclass (IgG 1), AUClast/Dose370.7 ± 53.0
IgG Subclass (IgG 2), AUCtau/Dose230.4 ± 25.2
IgG Subclass (IgG 2), AUClast/Dose197.4 ± 40.5
IgG Subclass (IgG 3), AUCtau/Dose7.916 ± 165.6
IgG Subclass (IgG 3), AUClast/Dose5.449 ± 227.2
IgG Subclass (IgG 4), AUCtau/Dose15.65 ± 37.1
IgG Subclass (IgG 4), AUClast/Dose12.08 ± 53.4
SecondaryEpoch 2: Half-life of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
Time frame:
At multiple time points post-infusion from Week 7 for participants with 4-Week or Week 4 with 3-Week dosing interval up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval
Reported as:
Median · day
Epoch 2: Half-life of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
dayEpoch 2: TAK-771 Full Dose Treatment Period
Total IgGNA (NA to NA)
IgG Subclass (IgG 1)59.7 (40.4 to 77.9)
IgG Subclass (IgG 2)49.6 (40.8 to 71.4)
IgG Subclass (IgG 3)NA (NA to NA)
IgG Subclass (IgG 4)35.9 (35.8 to 46.3)
SecondaryEpoch 2: Apparent Total Clearance (CL/F) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
Time frame:
Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Reported as:
Geometric mean · milliliters per day (mL/day)
Epoch 2: Apparent Total Clearance (CL/F) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
milliliters per day (mL/day)Epoch 2: TAK-771 Full Dose Treatment Period
Total IgG76.84 ± 29.4
IgG Subclass (IgG 1)117.0 ± 37.9
IgG Subclass (IgG 2)219.6 ± 36.8
IgG Subclass (IgG 3)6392 ± 176.6
IgG Subclass (IgG 4)3234 ± 58.0
SecondaryEpoch 2: Apparent Volume of Distribution (Vz/F) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
Time frame:
Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Reported as:
Geometric mean · mL
Epoch 2: Apparent Volume of Distribution (Vz/F) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
mLEpoch 2: TAK-771 Full Dose Treatment Period
Total IgGNA ± NA
IgG Subclass (IgG 1)8193 ± 54.9
IgG Subclass (IgG 2)14650 ± 57.0
IgG Subclass (IgG 3)NA ± NA
IgG Subclass (IgG 4)165900 ± 88.3
SecondaryEpoch 2: Minimum Concentration (Cmin) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
Time frame:
Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Reported as:
Geometric mean · g/L
Epoch 2: Minimum Concentration (Cmin) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
g/LEpoch 2: TAK-771 Full Dose Treatment Period
Total IgG9.347 ± 17.9
IgG Subclass (IgG 1)5.479 ± 10.7
IgG Subclass (IgG 2)2.941 ± 19.8
IgG Subclass (IgG 3)NA ± NA
IgG Subclass (IgG 4)0.2255 ± 8.4
SecondaryEpoch 2: Serum Trough Levels of IgG Subclasses (IgG1, IgG2, IgG3, and IgG4) After Administration of TAK-771
Time frame:
4-Week dosing interval (Week 7, Week 11, Week 15, Week 19, Week 23, Week 27, and Week 31); 3-Week dosing interval (Week 4, week 7, Week 10, Week 16, Week 19, Week 22, Week 25, and Week 28)
Reported as:
Geometric mean · g/L
Epoch 2: Serum Trough Levels of IgG Subclasses (IgG1, IgG2, IgG3, and IgG4) After Administration of TAK-771
g/LEpoch 2: TAK-771 Full Dose Treatment Period
IgG 1, Week 7, 4-Week Interval5.478 ± 12.1
IgG 1, Week 11, 4-Week Interval5.106 ± 15.6
IgG 1, Week 15, 4-Week Interval4.987 ± 11.9
IgG 1, Week 19, 4-Week Interval5.063 ± 10.1
IgG 1, Week 23, 4-Week Interval4.873 ± 10.8
IgG 1, Week 27, 4-Week Interval5.066 ± 16.6
IgG 1, Week 31, 4-Week Interval5.104 ± 14.0
IgG 2, Week 7, 4-Week Interval3.147 ± 20.1
IgG 2, Week 11, 4-Week Interval2.931 ± 15.0
IgG 2, Week 15, 4-Week Interval2.912 ± 13.5
IgG 2, Week 19, 4-Week Interval3.043 ± 16.5
IgG 2, Week 23, 4-Week Interval2.976 ± 16.7
IgG 2, Week 27, 4-Week Interval3.078 ± 15.5
IgG 2, Week 31, 4-Week Interval3.091 ± 18.3
IgG 3, Week 7, 4-Week Interval0.1380 ± NA
IgG 3, Week 11, 4-Week Interval0.1780 ± NA
IgG 3, Week 15, 4-Week Interval0.1390 ± NA
IgG 3, Week 27, 4-Week Interval0.2280 ± NA
IgG 4, Week 7, 4-Week Interval0.1933 ± 15.9
IgG 4, Week 11, 4-Week Interval0.1965 ± 22.7
IgG 4, Week 15, 4-Week Interval0.2020 ± 16.8
IgG 4, Week 19, 4-Week Interval0.2057 ± 16.1
IgG 4, Week 23, 4-Week Interval0.2054 ± 14.6
IgG 4, Week 27, 4-Week Interval0.2228 ± 24.6
IgG 4, Week 31, 4-Week Interval0.2265 ± 25.6
IgG 1, Week 4, 3-Week Interval9.699 ± 55.6
IgG 1, Week 7, 3-Week Interval8.906 ± 67.0
IgG 1, Week 10, 3-Week Interval8.661 ± 66.7
IgG 1, Week 16, 3-Week Interval8.860 ± 68.0
IgG 1, Week 19, 3-Week Interval8.687 ± 68.9
IgG 1, Week 22, 3-Week Interval8.641 ± 64.3
IgG 1, Week 25, 3-Week Interval8.573 ± 82.9
IgG 1, Week 28, 3-Week Interval8.845 ± 68.3
IgG 2, Week 4, 3-Week Interval1.936 ± 105.6
IgG 2, Week 7, 3-Week Interval1.859 ± 89.7
IgG 2, Week 10, 3-Week Interval1.852 ± 83.0
IgG 2, Week 16, 3-Week Interval1.964 ± 82.5
IgG 2, Week 19, 3-Week Interval1.944 ± 82.1
IgG 2, Week 22, 3-Week Interval1.957 ± 89.1
IgG 2, Week 25, 3-Week Interval1.910 ± 73.5
IgG 2, Week 28, 3-Week Interval1.948 ± 88.1
IgG 4, Week 4, 3-Week Interval0.1680 ± NA
IgG 4, Week 7, 3-Week Interval0.1680 ± NA
IgG 4, Week 10, 3-Week Interval0.2010 ± NA
IgG 4, Week 16, 3-Week Interval0.2280 ± NA
IgG 4, Week 19, 3-Week Interval0.2120 ± NA
IgG 4, Week 22, 3-Week Interval0.2230 ± NA
IgG 4, Week 25, 3-Week Interval0.2060 ± NA
IgG 4, Week 28, 3-Week Interval0.2390 ± NA
SecondaryEpoch 1 and 2: Trough Levels of Anti-Clostridium Tetani Toxoid Antibody After Administration of TAK-771
Time frame:
From Week 1, up to end of trial (EOS: Week 31 for participants with 4-Week dosing interval or Week 28 for participants with 3-Week dosing interval)
Reported as:
Geometric mean · IU/mL
Epoch 1 and 2: Trough Levels of Anti-Clostridium Tetani Toxoid Antibody After Administration of TAK-771
IU/mLEpoch 1 and 2
Week 11.334 ± 84.4
End of Trial (EOS)1.578 ± 68.4
SecondaryEpoch 1 and 2: Trough Levels of Anti-HBV Antibody After Administration of TAK-771
Time frame:
From Week 1, up to end of trial (EOS: Week 31 for participants with 4-Week dosing interval or Week 28 for participants with 3-Week dosing interval)
Reported as:
Geometric mean · mIU/mL
Epoch 1 and 2: Trough Levels of Anti-HBV Antibody After Administration of TAK-771
mIU/mLEpoch 1 and 2
Week 1278.38 ± 125.0
End of Trial (EOS)383.37 ± 57.7
SecondaryEpoch 1 and 2: Trough Levels of Anti-HIB Antibody After Administration of TAK-771
Time frame:
From Week 1, up to end of trial (EOS: Week 31 for participants with 4-Week dosing interval or Week 28 for participants with 3-Week dosing interval).
Reported as:
Geometric mean · ug/mL
Epoch 1 and 2: Trough Levels of Anti-HIB Antibody After Administration of TAK-771
ug/mLEpoch 1 and 2
Week 11.958 ± 45.7
End of Trial (EOS)1.519 ± 46.8
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

TEAEs are defined as Adverse events (AEs) with onset after date-time of first dose of Investigational product (IP), or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP.

Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)81.393.8
SecondaryPercentage of Participants With TAK-771-Related and TAK-771-Non-Related TEAEs

TEAEs are defined as AEs with onset after date-time of first dose of IP, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP.

Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percentage of participants
Percentage of Participants With TAK-771-Related and TAK-771-Non-Related TEAEs
percentage of participantsEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
TEAE Related56.368.8
TEAE Non-Related62.581.3
SecondaryPercentage of Participants With Serious and Non-serious TEAEs

TEAEs are defined as AEs with onset after date-time of first dose of IP, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Serious TEAE=any untoward clinical manifestation of signs, symptoms, outcomes (related to IP or not) at any dose: results in death, was life-threatening, requires inpatient/prolongation of hospitalization, resulted in persistent/significant disability/incapacity, congenital abnormality/birth defect, important medical event. AESI=investigator-reported hypersensitivity reactions, events of disordered coagulation as bleeding/hypercoagulable AESI.

Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percentage of participants
Percentage of Participants With Serious and Non-serious TEAEs
percentage of participantsEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Serious TEAEs6.36.3
Non-serious TEAEs81.393.8
SecondaryPercentage of Participants With Severe TEAEs
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · Percentage of participants
Percentage of Participants With Severe TEAEs
Percentage of participantsEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Percentage of Participants With Severe TEAEs06.3
SecondaryPercentage of Participants With Local and Systemic TEAEs
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percentage of participants
Percentage of Participants With Local and Systemic TEAEs
percentage of participantsEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Local TEAEs43.843.8
Systemic TEAEs75.087.5
SecondaryPercentage of Participants With TEAEs Leading to Premature Discontinuation From Study
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Premature Discontinuation From Study
percentage of participantsEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Percentage of Participants With TEAEs Leading to Premature Discontinuation From Study00
SecondaryPercentage of Participants With Infusion-associated TEAEs
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percentage of participants
Percentage of Participants With Infusion-associated TEAEs
percentage of participantsEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Percentage of Participants With Infusion-associated TEAEs37.550.0
SecondaryPercentage of Participants With Clinically Significant Changes in Clinical Laboratory Parameters Recorded as TEAEs
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Parameters Recorded as TEAEs
percentage of participantsEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Parameters Recorded as TEAEs00
SecondaryPercentage of Participants With Clinically Significant Changes in Vital Signs and Body Weight Recorded as TEAEs
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Changes in Vital Signs and Body Weight Recorded as TEAEs
percentage of participantsEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Percentage of Participants With Clinically Significant Changes in Vital Signs and Body Weight Recorded as TEAEs00
SecondaryEpoch 2: Percentage of Participants Who Develop Anti-rHuPH20 Binding Antibody Titers of Greater Than or Equal to 1:160
Time frame:
4-Week Dosing Interval (Week 7, Week 19, and Week 31); 3-Week Dosing Interval (Week 4, Week 16, and Week 28)
Reported as:
Number · percentage of participants
Epoch 2: Percentage of Participants Who Develop Anti-rHuPH20 Binding Antibody Titers of Greater Than or Equal to 1:160
percentage of participantsEpoch 2: TAK-771 Full Dose Treatment Period
Epoch 2: Percentage of Participants Who Develop Anti-rHuPH20 Binding Antibody Titers of Greater Than or Equal to 1:1600
SecondaryEpoch 2: Percentage of Participants Who Develop Neutralizing Antibodies to rHuPH20
Time frame:
4-Week Dosing Interval (Week 7, Week 19, and Week 31); 3-Week Dosing Interval (Week 4, Week 16, and Week 28)
Reported as:
Number · percentage of participants
Epoch 2: Percentage of Participants Who Develop Neutralizing Antibodies to rHuPH20
percentage of participantsEpoch 2: TAK-771 Full Dose Treatment Period
Epoch 2: Percentage of Participants Who Develop Neutralizing Antibodies to rHuPH200
SecondaryPercentage of Participants Who Experienced Tolerability Events Related to the Infusion of TAK-771

Tolerability events is defined as a case that the infusion rate is reduced, or that the infusion is interrupted or stopped, due to a TEAE related to TAK-771 infusion.

Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Tolerability Events Related to the Infusion of TAK-771
percentage of participantsEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Percentage of Participants Who Experienced Tolerability Events Related to the Infusion of TAK-77100
SecondaryEpoch 1: Number of Weeks to Reach Final Dose Interval (3 Weeks or 4 Weeks)

The number of weeks to reach final dose interval is defined as treatment duration of Epoch 1.

Time frame:
Up to Week 4 for Participants with 4-Week Dosing Interval or Up to Week 3 for Participants with 3-Week Dosing Interval
Reported as:
Median · weeks
Epoch 1: Number of Weeks to Reach Final Dose Interval (3 Weeks or 4 Weeks)
weeksEpoch 1: TAK-771 Ramp up Period
Epoch 1: Number of Weeks to Reach Final Dose Interval (3 Weeks or 4 Weeks)6.00 (3.0 to 6.9)
SecondaryEpoch 2: Percentage of Participants Who Achieve a Treatment Interval of 3 or 4 Weeks
Time frame:
Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percentage of participants
Epoch 2: Percentage of Participants Who Achieve a Treatment Interval of 3 or 4 Weeks
percentage of participantsEpoch 2: TAK-771 Full Dose Treatment Period
Epoch 2: Percentage of Participants Who Achieve a Treatment Interval of 3 or 4 Weeks100.0
SecondaryEpoch 2: Percentage of Participants Who Maintain a Treatment Interval of 3 or 4 Weeks
Time frame:
Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Number · percenatge of participants
Epoch 2: Percentage of Participants Who Maintain a Treatment Interval of 3 or 4 Weeks
percenatge of participantsEpoch 2: TAK-771 Full Dose Treatment Period
Epoch 2: Percentage of Participants Who Maintain a Treatment Interval of 3 or 4 Weeks100.0
SecondaryAnnual Rate of Validated Acute Serious Bacterial Infections (ASBIs) Per Participant Per Year

The annual rate of validated ASBIs is calculated as the mean number of ASBIs per participant per year.

Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Mean · ASBIs per participant per year
Annual Rate of Validated Acute Serious Bacterial Infections (ASBIs) Per Participant Per Year
ASBIs per participant per yearEpoch 1 and 2
Annual Rate of Validated Acute Serious Bacterial Infections (ASBIs) Per Participant Per Year0.00 ± 0.00
SecondaryAnnual Rate of All Infections Per Participant Per Year

The annual rate of all infections is calculated as the mean number of infections per participant per year.

Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Mean · infections per participant per year
Annual Rate of All Infections Per Participant Per Year
infections per participant per yearEpoch 1 and 2
Annual Rate of All Infections Per Participant Per Year2.69 ± 3.133
SecondaryHealthcare Resource Utilization: Days Not Able To Attend School/Work or To Perform Normal Daily Activities Due to Illness/Infection
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Median · number of days
Healthcare Resource Utilization: Days Not Able To Attend School/Work or To Perform Normal Daily Activities Due to Illness/Infection
number of daysEpoch 1 and 2
Healthcare Resource Utilization: Days Not Able To Attend School/Work or To Perform Normal Daily Activities Due to Illness/Infection0 (0 to 26.8)
SecondaryHealthcare Resource Utilization: Days on Antibiotics
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Median · number of days
Healthcare Resource Utilization: Days on Antibiotics
number of daysEpoch 1 and 2
Healthcare Resource Utilization: Days on Antibiotics0 (0 to 40.2)
SecondaryHealthcare Resource Utilization: Number of Hospitalizations Due to Illness/Infection Per Year
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Mean · hospitalizations per year
Healthcare Resource Utilization: Number of Hospitalizations Due to Illness/Infection Per Year
hospitalizations per yearEpoch 1 and 2
Healthcare Resource Utilization: Number of Hospitalizations Due to Illness/Infection Per Year0.22 ± 0.591
SecondaryHealthcare Resource Utilization: Length of Stay in Days of Hospitalizations Due to Illness/Infection Per Participant Per Year
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Median · hospitalization days/participant/year
Healthcare Resource Utilization: Length of Stay in Days of Hospitalizations Due to Illness/Infection Per Participant Per Year
hospitalization days/participant/yearEpoch 1 and 2
Healthcare Resource Utilization: Length of Stay in Days of Hospitalizations Due to Illness/Infection Per Participant Per Year0 (0 to 10.5)
SecondaryHealthcare Resource Utilization: Number of Acute (Urgent or Unscheduled) Physician Visits Due to Illness/Infection
Time frame:
From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Median · Acute Physician Visits
Healthcare Resource Utilization: Number of Acute (Urgent or Unscheduled) Physician Visits Due to Illness/Infection
Acute Physician VisitsEpoch 1 and 2
Healthcare Resource Utilization: Number of Acute (Urgent or Unscheduled) Physician Visits Due to Illness/Infection1.74 (0 to 11.7)
SecondaryInfusion Parameters in Epoch 2: Number of Infusion Sites Per Infusion

Total number of infusion sites injected in Epoch 2 / Total number of infusions administered in Epoch 2.

Time frame:
From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Mean · infusion sites per infusion
Infusion Parameters in Epoch 2: Number of Infusion Sites Per Infusion
infusion sites per infusionEpoch 2: TAK-771 Full Dose Treatment Period
Infusion Parameters in Epoch 2: Number of Infusion Sites Per Infusion1.77 ± 0.394
SecondaryInfusion Parameters in Epoch 2: Number of Infusion Sites Per Month

Total number of infusion sites injected in Epoch 2 / (duration of Epoch 2 / 30.4375), where duration of Epoch 2 is calculated as the end date of the Epoch 2 - the start date of the Epoch 2 + 1.

Time frame:
From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Mean · infusion sites per month
Infusion Parameters in Epoch 2: Number of Infusion Sites Per Month
infusion sites per monthEpoch 2: TAK-771 Full Dose Treatment Period
Infusion Parameters in Epoch 2: Number of Infusion Sites Per Month2.02 ± 0.514
SecondaryInfusion Parameters in Epoch 2: Duration of Individual Infusions

End date and time of infusion in Epoch 2 - Start date and time of infusion in Epoch 2, for each infusion per participant.

Time frame:
From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Median · minutes
Infusion Parameters in Epoch 2: Duration of Individual Infusions
minutesEpoch 2: TAK-771 Full Dose Treatment Period
Infusion Parameters in Epoch 2: Duration of Individual Infusions74.0 (18 to 207)
SecondaryInfusion Parameters in Epoch 2: Maximum Infusion Rate Per Site

Maximum Infusion Rate results from CRF / number of infusion sites/body.

Time frame:
From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Mean · mL/hour per site
Infusion Parameters in Epoch 2: Maximum Infusion Rate Per Site
mL/hour per siteEpoch 2: TAK-771 Full Dose Treatment Period
Infusion Parameters in Epoch 2: Maximum Infusion Rate Per Site222.3 ± 83.77
SecondaryInfusion Parameters in Epoch 2: Infusion Volume Per Site

Infusion Volume per Site is scheduled Dose results from CRF / number of infusion sites/body.

Time frame:
From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Mean · mL/site
Infusion Parameters in Epoch 2: Infusion Volume Per Site
mL/siteEpoch 2: TAK-771 Full Dose Treatment Period
Infusion Parameters in Epoch 2: Infusion Volume Per Site117.3 ± 77.73
SecondaryQuality of Life (QOL): Pediatric Quality of Life Inventory (PEDS-QL)

The PEDS-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. In this study, 2-7 years (parent as observer), 8-13 years (participant as observer) for PEDS-QL health questionnaire will be analyzed. Higher scores indicate better quality of life (QOL) for all domains of the PEDS-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Four dimensions (physical, emotional, social, \& school functioning) are scored.

Time frame:
4-Week Dosing Interval (Week 1 and Week 31); 3-Week Dosing Interval (Week 1 and Week 28)
Reported as:
Mean · score on a scale
Quality of Life (QOL): Pediatric Quality of Life Inventory (PEDS-QL)
score on a scaleEpoch 1 and 2
Baseline (Week 1), 2-7 years, Total score, 4-week interval93.48 ± NA
Baseline (Week 1), 2-7 years, Total score, 3-week interval76.09 ± NA
Baseline (Week 1), 8-13 years, Total score, 4-week interval77.17 ± 18.091
Change from Baseline (EOS/ET),2-7 years, Total score, 4-week interval2.17 ± NA
Change from Baseline (EOS/ET),2-7 years, Total score, 3-week interval11.96 ± NA
Change from Baseline (EOS/ET), 8-13 years, Total score, 4-week interval11.41 ± 3.843
SecondaryQOL: Short Form-36 Health Survey Version 2 (SF-36 v2)

The SF-36 is a generic quality-of-life instrument that has been widely used to assess Health-Related Quality of Life (HR QoL) of participants. In this study, 14 years and older (participant as observer) for SF-36 health questionnaire will be analyzed. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HR QoL. Physical component summary (PCS).

Time frame:
4-Week Dosing Interval (Week 1 and Week 31); 3-Week Dosing Interval (Week 1 and Week 28)
Reported as:
Mean · score on a scale
QOL: Short Form-36 Health Survey Version 2 (SF-36 v2)
score on a scaleEpoch 1 and 2
Baseline (Week 1), 14 years and older, Physical component summary (PCS) score, 4-week interval51.85 ± 3.458
Baseline (Week 1), 14 years and older, Physical component summary (PCS) score, 3-week interval53.30 ± 2.546
Baseline (Week 1), 14 years and older, Mental component summary (MCS) score 4-week interval51.38 ± 14.060
Baseline (Week 1), 14 years and older, Mental component summary (MCS) score 3-week interval59.90 ± 10.465
Baseline (Week 1), >=14 years, Role/social component summary (RCS) score, 4-week interval49.67 ± 8.495
Baseline (Week 1), >=14 years, Role/social component summary (RCS) score, 3-week interval53.50 ± 8.768
Change from Baseline (EOS/ET), >=14 years, Physical component summary (PCS) score, 4-week interval0.20 ± 8.709
Change from Baseline (EOS/ET), >=14 years, Physical component summary (PCS) score, 3-week interval-1.85 ± 1.202
Change from Baseline (EOS/ET), >=14 years, Mental component summary (MCS) score 4-week interval-3.12 ± 5.605
Change from Baseline (EOS/ET), >=14 years, Mental component summary (MCS) score 3-week interval-3.55 ± 0.636
Change from Baseline (EOS/ET), >=14 years, Role/social component summary (RCS) score 4-week interval-0.80 ± 6.592
Change from Baseline (EOS/ET), >=14 years, Role/social component summary (RCS) score,3-week interval4.90 ± 3.394
SecondaryQOL: EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Health Questionnaire Index Score

The EQ-5D-3L is a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. Participants select answer for each of the following 3-level dimensions: 1) mobility; 2) self-care; 3) usual activities; 4) pain/discomfort; 5) anxiety/depression used to compute an index score ranging from 0 (worst imaginable health state) to 1 (best imaginable health state). An increase in the EQ-5D-3L index score indicates improvement.

Time frame:
4-Week dosing interval (Week 1 and Week 31); 3-Week dosing interval (Week 1 and Week 28)
Reported as:
Mean · score on a scale
QOL: EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Health Questionnaire Index Score
score on a scaleEpoch 1 and 2
Baseline (Week 1), 2-11 years, EQ-5D index score, 4-week interval1.0000 ± 0.00000
Baseline (Week 1), 2-11 years, EQ-5D index score, 3-week interval0.6750 ± NA
Baseline (Week 1), 12 years and older, EQ-5D index score, 4-week interval0.9271 ± 0.12655
Baseline (Week 1), 12 years and older, EQ-5D index score, 3-week interval1 ± 0
Change from Baseline (EOS/ET), 2-11 years, EQ-5D index score, 4-week interval0.0000 ± NA
Change from Baseline (EOS/ET), 2-11 years, EQ-5D index score, 3-week interval0.3250 ± NA
Change from Baseline (EOS/ET), 12 years and older, EQ-5D index score, 4-week interval0.0729 ± 0.12655
Change from Baseline (EOS/ET), 12 years and older, EQ-5D index score, 3-week interval0.0000 ± 0.00000
SecondaryQOL: EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Health Questionnaire Visual Analogue Scale (VAS) Score

The EQ-5D-3L is a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. The EQ-5D-3L includes a visual analog scale (VAS), a vertical scale that allows the participants to indicate their health state that day, and ranges from 0 (worst imaginable) to 100 (best imaginable), with higher scores indicating better health state.

Time frame:
4-Week dosing interval (Week 1 and Week 31); 3-Week dosing interval (Week 1 and Week 28)
Reported as:
Mean · score on a scale
QOL: EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Health Questionnaire Visual Analogue Scale (VAS) Score
score on a scaleEpoch 1 and 2
Baseline (Week 1), 2-11 years, EQ-5D VAS score, 4-week interval95.0 ± 7.07
Baseline (Week 1), 2-11 years, EQ-5D VAS score, 3-week interval100.0 ± NA
Baseline (Week 1), 12 years and older, EQ-5D VAS score, 4-week interval76.3 ± 13.24
Baseline (Week 1), 12 years and older, EQ-5D VAS score, 3-week interval85.0 ± 7.07
Change from Baseline (EOS/ET), 2-11 years, EQ-5D VAS score, 4-week interval-5.0 ± NA
Change from Baseline (EOS/ET), 2-11 years, EQ-5D VAS score, 3-week interval-10 ± NA
Change from Baseline (EOS/ET), 12 years and older, EQ-5D VAS score, 4-week interval6.3 ± 9.78
Change from Baseline (EOS/ET), 12 years and older, EQ-5D VAS score, 3-week interval-2.5 ± 3.54
SecondaryTreatment Preference

Treatment preference questionnaire is a self-administered questionnaire developed to assess participants' preference towards the administration of new subcutaneous immunoglobulin (SCIG) therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin (IG) therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment.

Time frame:
Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval
Reported as:
Count of participants · Participants
Treatment Preference
ParticipantsEpoch 1 and 2
2-13 years, Before your participation in trial, where did you receive your IG therapy?=At hospital4
2-13 years, Before your participation in the trial, where did you receive your IG therapy?=At home2
2-13 years, Where do you prefer to receive your immunoglobulin therapy?=At hospital2
2-13 years, Where do you prefer to receive your IG therapy?=At home1
2-13 years, Where do you prefer to receive your IG therapy?=No Preference2
2-13 years, frequency of administration=Like very much3
2-13 years, frequency of administration=Like1
2-13 years, Frequency of administration=No Preference1
2-13 years, number of needlesticks per month=Like very much2
2-13 years, number of needlesticks per month=Like2
2-13 years, number of needlesticks per month=No preference1
2-13 years, total time spent for my treatment per month=Like3
2-13 years, total time spent for my treatment per month=No Preference2
2-13 years, ease of administration= Like1
2-13 years, ease of administration= No Preference3
2-13 years, The ease of administration= Dislike1
2-13 years, potential to self-administer=Like very much1
2-13 years, potential to self-administer=No preference2
2-13 years, potential to self-administer=Dislike1
2-13 years, potential to self-administer=Dislike very much1
2-13 years, ability to fit my treatment into my own schedule= Like3
2-13 years, ability to fit my treatment into my own schedule= No Preference2
2-13 years, overall convenience=Like4
2-13 years, overall convenience=No preference1
2-13 years, amount of time administration takes=Like2
2-13 years, amount of time administration takes=No preference2
2-13 years, amount of time administration takes=Dislike1
2-13 years, complexity of administration process=Like2
2-13 years, complexity of administration process=No preference2
2-13 years, complexity of administration process=Dislike1
2-13 years, My ability to self-administer without medical supervision=Like very much1
2-13 years, My ability to self-administer without medical supervision=No preference1
2-13 years, My ability to self-administer without medical supervision=Dislike1
2-13 years, My ability to self-administer without medical supervision=Dislike very much2
2-13 years, would you choose to continue receiving your treatment using IGg10% with rHuPH20 SC?=Yes5
14 years and older, Before your participation, where did you receive your IG therapy?=At hospital8
14 years and older, Before your participation, where did you receive your IG therapy?=At home7
14 years and older, Before your participation, where did you receive your IG therapy?=Other1
14 years and older, Where do you prefer to receive your IG therapy? = At hospital2
14 years and older, Where do you prefer to receive your IG therapy? = At home7
14 years and older, Where do you prefer to receive your IG therapy? = No preference2
14 years and older, frequency of administration=Like very much3
14 years and older, frequency of administration=Like7
14 years and older, frequency of administration=No preference1
14 years and older, number of needlesticks per month=Like8
14 years and older, number of needlesticks per month=No preference3
14 years and older, total time spent for my treatment per month = Like very much1
14 years and older, total time spent for my treatment per month=Like6
14 years and older, total time spent for my treatment per month=No preference2
14 years and older, total time spent for my treatment per month=Dislike2
14 years and older, ease of administration=Like2
14 years and older, ease of administration=No preference2
14 years and older, ease of administration=Dislike6
14 years and older, ease of administration=Dislike very much1
14 years and older, potential to self-administer=Like8
14 years and older, The potential to self-administer = No preference1
14 years and older, potential to self-administer=Dislike1
14 years and older, potential to self-administer=Dislike very much1
14 years and older, ability to fit my treatment into my own schedule= Like very much1
14 years and older, ability to fit my treatment into my own schedule= Like7
14 years and older, ability to fit my treatment into my own schedule= No preference2
14 years and older, ability to fit my treatment into my own schedule= Dislike1
14 years and older, overall convenience = Like8
14 years and older, overall convenience = No preference2
14 years and older, overall convenience = Dislike1
14 years and older, amount of time administration takes = Like7
14 years and older, amount of time administration takes = No preference3
14 years and older, amount of time administration takes = Dislike1
14 years and older, complexity of administration process=Like very much1
14 years and older, complexity of administration process=Like1
14 years and older, complexity of administration process=No preference2
14 years and older, complexity of administration process=Dislike6
14 years and older, complexity of administration process=Dislike very much1
14 years and older, My ability to self-administer without medical supervision=Like very much1
14 years and older, My ability to self-administer without medical supervision=Like6
14 years and older, My ability to self-administer without medical supervision = No preference1
14 years and older, My ability to self-administer without medical supervision = Dislike2
14 years and older, My ability to self-administer without medical supervision = Dislike very much1
14 years and older, choose to continue receiving your treatment using IGg 10% with rHuPH20 SC?=Yes9
14 years and older, choose to continue receiving your treatment using IGg 10% with rHuPH20 SC?= No2
SecondaryTreatment Satisfaction: Questionnaire for Medication-9 (TSQM-9)

Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. In this study, 2-12 years (parent as observer), 13 years and older (participant as observer) for TSQM health questionnaire will be analyzed. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.

Time frame:
4-Week dosing interval (Week 1 and Week 31); 3-Week dosing interval (Week 1 and Week 28)
Reported as:
Mean · score on a scale
Treatment Satisfaction: Questionnaire for Medication-9 (TSQM-9)
score on a scaleEpoch 1 and 2
Baseline (Week 1), 2-12 years, Effectiveness, 4-week interval64.81 ± 3.208
Baseline (Week 1), 2-12 years, Effectiveness, 3-week interval94.44 ± NA
Baseline (Week 1), 2-12 years, Convenience, 4-week interval44.44 ± 19.245
Baseline (Week 1), 2-12 years, Convenience, 3-week interval38.89 ± NA
Baseline (Week 1), 2-12 years, Global satisfaction, 4-week interval59.52 ± 10.911
Baseline (Week 1), 2-12 years, Global satisfaction, 3-week interval100.00 ± NA
Baseline (Week 1), 13 years and older, Effectiveness, 4-week interval64.81 ± 18.812
Baseline (Week 1), 13 years and older, Effectiveness, 3-week interval63.89 ± 3.928
Baseline (Week 1), 13 years and older, Convenience, 4-week interval62.04 ± 19.694
Baseline (Week 1), 13 years and older, Convenience, 3-week interval44.44 ± 0.000
Baseline (Week 1), 13 years and older, Global satisfaction, 4-week interval60.71 ± 8.748
Baseline (Week 1), 13 years and older, Global satisfaction, 3-week interval64.29 ± 10.102
Change from Baseline (EOS/ET), 2-12 years, Effectiveness, 4-week interval0.00 ± 0.000
Change from Baseline (EOS/ET), 2-12 years, Effectiveness, 3-week interval-27.78 ± NA
Change from Baseline (EOS/ET), 2-12 years, Convenience, 4-week interval13.89 ± 3.928
Change from Baseline (EOS/ET), 2-12 years, Convenience, 3-week interval0.00 ± NA
Change from Baseline (EOS/ET), 2-12 years, Global satisfaction, 4-week interval10.71 ± 5.051
Change from Baseline (EOS/ET), 2-12 years, Global satisfaction, 3-week interval-28.57 ± NA
Change from Baseline (EOS/ET), 13 years and older, Effectiveness, 4-week interval-12.04 ± 26.156
Change from Baseline (EOS/ET), 13 years and older, Effectiveness, 3-week interval2.78 ± 3.928
Change from Baseline (EOS/ET), 13 years and older, Convenience, 4-week interval-3.70 ± 20.688
Change from Baseline (EOS/ET), 13 years and older, Convenience, 3-week interval0.00 ± 7.857
Change from Baseline (EOS/ET), 13 years and older, Global satisfaction, 4-week interval-13.10 ± 26.885
Change from Baseline (EOS/ET), 13 years and older, Global satisfaction, 3-week interval-3.57 ± 5.051

Adverse events

Collected over From study start up to Week 28 for the 3-week dosing intervals and up to Week 31 for 4-week dosing intervals. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoch 1: TAK-771 Ramp up Period0/16 (0%)1/16 (6.3%)13/16 (81.3%)
Epoch 2: TAK-771 Full Dose Treatment Period0/16 (0%)1/16 (6.3%)15/16 (93.8%)
Most frequent serious events
Most frequent serious events
EventEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
Adrenal insufficiencyEndocrine disorders1/160/16
GastroenteritisInfections and infestations1/160/16
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders0/161/16
Most frequent other events
Showing 10 of 54
Most frequent other events
EventEpoch 1: TAK-771 Ramp up PeriodEpoch 2: TAK-771 Full Dose Treatment Period
PyrexiaGeneral disorders5/165/16
NasopharyngitisInfections and infestations3/163/16
COVID-19Infections and infestations0/162/16
Chronic sinusitisInfections and infestations0/162/16
HeadacheNervous system disorders2/161/16
Infusion site erythemaGeneral disorders2/162/16
Infusion site painGeneral disorders2/160/16
Infusion site swellingGeneral disorders2/161/16
Injection site erythemaGeneral disorders2/162/16
Injection site painGeneral disorders2/162/16

Baseline characteristics

Safety Analysis Set (SAS) included all enrolled subjects who received investigational drug at least once. Analyses of safety, tolerability and product administration were based on the SAS.

Age, Continuous
Age, Continuous(Years)Epoch 1: TAK-771
Mean25.2 ± 16.86
Sex: Female, Male
Sex: Female, Male(Participants)Epoch 1: TAK-771
Female6
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Epoch 1: TAK-771
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Epoch 1: TAK-771
American Indian or Alaska Native0
Asian16
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Epoch 1: TAK-771
Japan16
Height at Baseline
Height at Baseline(Centimeters (cm))Epoch 1: TAK-771
Mean149.26 ± 25.892
Weight at Baseline
Weight at Baseline(Kilograms (kg))Epoch 1: TAK-771
Mean44.33 ± 16.509
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter square (kg/m^2))Epoch 1: TAK-771
Mean19.05 ± 2.747
08

Study locations

12 sites
  • Nagoya University Hospital
    Nagoya, Aichi, Japan
  • Hospital of University of Occupational and Environmental Health
    Kitakyushu, Fukuoka, Japan
  • Kurume University Hospital
    Kurume, Fukuoka, Japan
  • Kanagawa Children's Medical Center
    Yokohama, Kanagawa, Japan
  • Shinshu University Hospital
    Matsumoto, Nagano, Japan
  • Tokyo Medical Dental University Hospital
    Bunkyo-ku, Tokyo, Japan
  • National Center for Child Health and development
    Setagaya-ku, Tokyo, Japan
  • Kyushu University Hospital
    Fukuoka, Japan
  • Gifu University Hospital
    Gifu, Japan
  • Hiroshima University Hospital
    Hiroshima, Japan
  • Saitama Prefectual Children's Medical Center
    Saitama, Japan
  • Shizuoka Childrens Hospital
    Shizuoka, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Aug 2023, 19 months.

Results were first posted in Nov 2024, 1 year 2 months after primary completion.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2021
First posted
Dec 9, 2021
StartActual
Jan 24, 2022
Primary completionActual
Aug 28, 2023
CompletionActual
Aug 28, 2023
Results first posted
Nov 25, 2024
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05150340
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Jan 24, 2022
Primary completion
Aug 28, 2023
Completion
Aug 28, 2023
Results posted
Nov 25, 2024
Last update
Nov 25, 2024

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins

Start the discussion